Mavorixafor: First Approval.
Drugs
; 84(8): 969-975, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-39004659
ABSTRACT
Mavorixafor (XOLREMDI™) is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist developed by X4 Pharmaceuticals that blocks the binding of C-X-C chemokine ligand 12 (also known as stromal derived factor-1) to CXCR4. In April 2024, it became the first therapy to be approved for WHIM syndrome (named by an acronym for its observed characteristics of Warts, Hypogammaglobulinaemia, Infections and Myelokathexis) in the USA, where it is indicated for use in patients aged ≥â¯12 years with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes. Clinical development of mavorixafor is ongoing for chronic neutropenic disorders. This article summarizes the milestones in the development of mavorixafor leading to this first approval for use in patients aged ≥â¯12 years with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aprovação de Drogas
/
Receptores CXCR4
/
Doenças da Imunodeficiência Primária
Limite:
Child
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Drugs
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Nova Zelândia
País de publicação:
Nova Zelândia